In the evolving landscape of drug development for neurological conditions, one tool remains underutilized, yet it holds the potential to revolutionize the field: electroencephalography (EEG). As we delve deeper into neurodegenerative disorders like Alzheimer’s, Parkinson’s, or neurodevelopmental like autism, ADHD and fragile X syndrome (FXS), the need for more precise outcome measures in clinical trials becomes evident. EEG is emerging as a promising solution, providing insights that other methods simply can’t.
Bridging Preclinical and Clinical Gaps in Fragile X Syndrome
A pivotal study in Translational Psychiatry, part of the Nature portfolio, underlines a recurring issue: while treatments show promise in the lab, they often fail in clinical trials. Why the discrepancy? One major factor is the lack of sensitive and reliable biomarkers that can predict success in human subjects. According to the authors, EEG offers a solution by identifying brain activity patterns that directly correspond to those observed in preclinical models. In FXS, for example, EEG has revealed abnormalities like increased N1 ERP amplitudes and disrupted gamma activity—patterns that mirror findings in animal models.
By leveraging EEG, researchers could better translate preclinical successes into clinical breakthroughs, ensuring that promising treatments for FXS and other neurodevelopmental disorders don’t fall short in later stages.
EEG’s Expanding Role Beyond Seizure Monitoring
Traditionally associated with epilepsy, EEG is now recognized as a powerful tool for broader neurological applications. A recent article by Deborah Borfitz in Clinical Research News raises concerns about the underutilization of EEG in trials for drugs targeting conditions like Alzheimer’s disease and even psychedelics, which have profound effects on brain function. Despite its potential to track cognitive changes and neurophysiological responses, EEG remains underused in many studies.
This is a missed opportunity, as EEG can serve not only as a safety measure for detecting seizure risk but also as an outcome measure for assessing drug efficacy and brain function. In fact, some clinical trials have already shown that EEG changes correlate with clinical improvements, offering a more nuanced understanding of how treatments work.
Why EEG Should Be a Staple in CNS Drug Development
As drug development in central nervous system (CNS) disorders grows, EEG is poised to play a crucial role in improving both safety and efficacy assessments. For pharmaceutical companies and researchers involved in these studies, integrating EEG into clinical trials can provide more robust data on brain activity changes in response to treatments, allowing for a clearer understanding of their impact.
At Starlab, we’re committed to advancing the use of EEG in clinical trials for Alzheimer’s, Parkinson’s, and neurodevelopmental disorders. With our comprehensive EEG analysis services, we’re helping researchers bridge the gap between preclinical models and real-world results, making it possible to develop more effective treatments faster.
💬 Want to learn more about how EEG can benefit your clinical trials?
Contact us today to explore how this cutting-edge technology can enhance your research. Visit our website or reach out at info@starlab.es for further inquiries!
Comentarios